Earnings call Nektar ended 2025 with $245.8M in cash and no debt, bolstered by an additional $476M in early 2026. REZPEG advanced to phase 3 in atopic dermatitis with phase 3 initiation set for June ...
Add Yahoo as a preferred source to see more of our stories on Google. Whether readers own paperbacks, audiobooks, or ebooks, they expect the text to remain the same, unless a glaring issue or typo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results